October 23rd 2024
Recent advancements in protein engineering, especially antibody-drug conjugates, show promise in lung cancer treatment, with ivonescimab outperforming pembrolizumab in PD-L1-positive advanced non-small cell lung cancer.
September 30th 2024
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Molecular Targets in Non-Small Cell Lung Cancer
November 15th 2013Today, the treatment options for non-small cell lung cancer (NSCLC) in the United States include targeted therapies aimed at angiogenesis (bevacizumab), EGFR mutations (erlotinib and afatinib), and ALK translocations (crizotinib).
Read More
Multidisciplinary Perspectives: Molecular Testing in NSCLC
November 15th 2013Testing for genetic abnormalities is important in NSCLC, both to ensure that as many patients as possible are benefit from approved therapies and to advance understanding of more targets that may be able to lead to future treatments.
Read More
Afatinib for <em>EGFR</em> Mutation-Positive, Advanced Non-Small Cell Lung Cancer
November 11th 2013Activating EGFR mutations are associated with response to TKIs. Afatinib (Gilotrif) is an oral, irreversible ErbB family TKI that targets EGFR, HER2, and ErbB4. Afatinib is being formally evaluated in the LUX-Lung clinical trial program for NSCLC.
Read More
The Risk of Pneumonitis From Radiation in Patients With Lung Cancer
October 9th 2013Laurie Gaspar, MD, Professor and Chair Department of Radiation Oncology, Grohne Chair in Clinical Oncology, University of Colorado School of Medicine, discusses the risk of pneumonitis from radiation among patients with lung cancer.
Watch
Anti-PD-1 Antibody MK-3475 Shows Promise in NSCLC
October 3rd 2013MK-3475, an investigational immunotherapy, has demonstrated an objective response rate (ORR) of up to 24% in patients with previously treated non-small cell lung cancer (NSCLC), according to interim results from a phase Ib expansion study.
Read More
Advances in Non-Small Cell Lung Cancer
September 30th 2013Individualized treatment protocols for patients are becoming increasingly important in the management of NSCLC. Consequently, drug research continues to focus on regimens that select therapy according to the molecular characteristics of the tumor.
Read More